IBG Beteiligungsgesellschaft Sachsen-Anhalt

InLine-Med GmbH, established in 2019 and based in Magdeburg, Germany, specializes in developing assistance devices that enhance the efficiency and accuracy of needle-based interventions for radiologists. The company offers a range of products, including navigation devices, surgical tools, needle alignment tools, and anatomical marker grids, along with navigation software that aids in visualization and intervention planning. By integrating artificial intelligence with innovative guiding tools and high-quality biopsy needles, InLine-Med addresses the challenges of accurate needle placement, which is crucial in cancer diagnosis and treatment. Their solution allows clinicians to define a needle trajectory on a computer and seamlessly translate this plan to the patient, minimizing the need for multiple punctures and reducing procedure times. The comprehensive suite of assistance tools is competitively priced, enabling clinicians to conduct safe and precise interventions without relying on complex robotic systems.

COMAN Software GmbH specializes in developing software solutions tailored for machine and plant construction. Founded in 2018 and headquartered in Gardelegen, Germany, the company offers a project management platform that enhances efficiency and transparency in construction projects. Key features include real-time data capture, easy import of project data, automated status report generation, and mobile access to project information. This software aims to optimize project planning and execution, reduce construction times, and minimize errors through centralized data management and streamlined communication. Additionally, COMAN Software provides various services, including support, training, and consulting, to assist clients in effectively utilizing their platform. The company's innovative approach enables businesses to enhance collaboration, stay on schedule, and manage projects within budget.

Lab-on-Fiber GmbH, based in Halle, Germany, specializes in the development and production of advanced medical laser probes and systems aimed at enhancing minimally invasive surgical procedures. The company offers a range of fiber delivery systems, including surgical and urology fiber probes. By providing optimized radiation profiles and real-time temperature monitoring at the probe surface, Lab-on-Fiber's technology helps surgeons reduce operating times, improve treatment outcomes, and enhance patient safety. Their innovative solutions are designed to streamline laser surgery while minimizing potential complications, positioning Lab-on-Fiber as a key player in the medical technology sector.

TESVOLT GmbH, established in 2014 and headquartered in Wittenberg, Germany, specializes in the development and manufacturing of lithium battery storage systems aimed at the commercial and industrial sectors. As a recognized leader in energy storage solutions in Germany and Europe, TESVOLT produces intelligent lithium storage systems with power capacities ranging from 10 kilowatt hours to several megawatt hours, all manufactured in a carbon-neutral gigafactory. Their products facilitate companies in reducing energy dependency and contribute to the transition toward renewable energy sources, including solar, wind, and biogas. The company has been acknowledged with various awards for its innovative approaches, driven by its co-founders Daniel Hannemann and Simon Schandert, who have extensive experience in the photovoltaic sector. TESVOLT's focus on developing economical storage solutions is complemented by its commitment to safety and quality, as evidenced by TÜV certification for its products.

Arzneimittelwerk Warngau develops and markets drug delivery systems. Its portfolio includes active ingredient/biodegradable implants and transdermal systems in the areas of oncology, pain therapy, and neurology. It focuses on transdermal passive and microchip controlled patches, as well as subcutaneous biodegradable implants. Wilfried Fischer founded Arzneimittelwerk Warngau in 2008. It has its headquarters in Warngau in Germany.

Arzneimittelwerk Warngau develops and markets drug delivery systems. Its portfolio includes active ingredient/biodegradable implants and transdermal systems in the areas of oncology, pain therapy, and neurology. It focuses on transdermal passive and microchip controlled patches, as well as subcutaneous biodegradable implants. Wilfried Fischer founded Arzneimittelwerk Warngau in 2008. It has its headquarters in Warngau in Germany.

Micropelt started as a project of Infineon Technologies AG in cooperation with the Fraunhofer Institute for Physical Measurement Techniques (Fraunhofer IPM) in Freiburg (Germany). Now it is a StartUp which is funded by SHS, MBG, KfW Mittelstandsbank, L-Bank and IBG. Their team develops thin film thermoelectric components based on semiconductor manufacturing processes.

Vivoryon Therapeutics AG is a clinical-stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products aimed at treating Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has successfully completed Phase IIb clinical trials for Alzheimer's treatment. Additionally, Vivoryon is advancing PQ1565, another small molecule targeting cancer, and is developing a monoclonal antibody to enhance the clearance of toxic pyroglutamate-Abeta (pGlu-Abeta). The company has established research collaborations with University Medical Center Schleswig-Holstein, Nordic Bioscience, and the Fraunhofer Institute, focusing on cancer immunotherapy and the clinical development of its candidates. Founded in 1997 and originally named Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.

Vivoryon Therapeutics AG is a clinical-stage biopharmaceutical company based in Halle, Germany, specializing in the research and development of therapeutic products aimed at treating Alzheimer's disease and cancer. The company's lead candidate, PQ912, is a small molecule QC inhibitor that has successfully completed Phase IIb clinical trials for Alzheimer's treatment. Additionally, Vivoryon is advancing PQ1565, another small molecule targeting cancer, and is developing a monoclonal antibody to enhance the clearance of toxic pyroglutamate-Abeta (pGlu-Abeta). The company has established research collaborations with University Medical Center Schleswig-Holstein, Nordic Bioscience, and the Fraunhofer Institute, focusing on cancer immunotherapy and the clinical development of its candidates. Founded in 1997 and originally named Probiodrug AG, the company rebranded to Vivoryon Therapeutics AG in June 2019.

EUCODIS Bioscience GmbH is a manufacturer of enzyme solutions that cater to various industries, including biopharma, fine chemicals, and cosmetics. Established in 2007 and based in Vienna, Austria, with a subsidiary in Germany, the company produces a diverse range of enzymes such as lipases, peroxidases, and nitrile hydratases. These enzymes facilitate applications including the stereospecific resolution of chiral alcohols and acids for active pharmaceutical ingredient synthesis, the production of sensitive esters, and the selective hydrolysis of fatty acids. Additionally, EUCODIS offers services in protein and enzyme engineering, bioprocess development, and industrial manufacturing. Their products are utilized by leading companies in the chemical, pharmaceutical, food, and cosmetics sectors to enhance production efficiency and comply with environmental standards.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading drug candidates, NOX-A12 and NOX-E36, derived from a novel class of therapeutics known as Spiegelmers. These compounds are designed to improve the effectiveness of existing cancer therapies by offering specific advantages over traditional drug classes. TME Pharma maintains a strategic alliance with Pfizer, Inc., underscoring its commitment to advancing innovative treatment options in oncology. The company is headquartered in Berlin, Germany.